Teva breached antitrust rules over Copaxone, says EU

European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be found to have infringed Article 102 of TFEU.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Teva and Apotex prevail in sleep drug dispute

11 May 2023 The dispute centred on a treatment that helps people adjust their circadian rhythm | Path now clear for generic drug makers to unveil biosimilar versions of the drug.

Big Pharma

Teva secures victory in iron overload treatment dispute

17 November 2022 Judge Hacon rules that a skilled team “would have thought it obvious” to reformulate drug into a tablet | Teva DFX patents also found not to infringe, falling outside the claims on both a normal construction and under the doctrine of equivalents.

Big Pharma

Teva settles patent dispute with Aurobindo

13 June 2022 Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.